Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference - Seite 2
About Kuros Biosciences
Kuros Biosciences is a fast-growing leader in the development of spinal fusion biologics that ease the burden of back pain. With locations in the United States, Switzerland and the Netherlands, the
company is listed on the SIX Swiss Exchange. The company’s first commercial product, MagnetOs, is a unique advanced bone graft that has already been used successfully across three continents
and in over 25,000 fusion surgeries.
Lesen Sie auch
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any
future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other
similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for
updating forward-looking statements or adapting them to future events or developments.
1. Duan, et al. eCM. 2019;37:60-73
2. Van Dijk, et al. eCM. 2021;41:756-73
3. Van Dijk, et al. JOR Spine. 2018;e1039
4. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090
5. Van Dijk, et al. Clin Spine Surg. 2020;33(6):E276–E287
*In large animal models
†Results from in vivo laboratory testing may not be predictive of clinical experience in humans.
For important safety and intended use information please visit kurosbio.com
‡MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft
§For a 510(k)-cleared synthetic bone graft
¶MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
For further information, please contact:
Kuros Biosciences AG |